Literature DB >> 12594127

Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.

G Licata, A Pinto, A Tuttolomondo, A Banco, F Ciccia, A Ferrante, G Triolo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12594127      PMCID： PMC1754467          DOI： 10.1136/ard.62.3.280

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  16 in total

1.  The diagnostic conundrum of primary angiitis of the central nervous system: a case report.

Authors:  Dipender Gill; Stephan Hinze; Jacqueline Palace
Journal:  J Neurol       Date:  2010-11-23       Impact factor: 4.849

2.  Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.

Authors:  K Fujikawa; K Aratake; A Kawakami; T Aramaki; N Iwanaga; Y Izumi; K Arima; M Kamachi; M Tamai; M Huang; H Nakamura; Y Nishiura; T Origuchi; H Ida; K Eguchi
Journal:  Ann Rheum Dis       Date:  2007-01       Impact factor: 19.103

3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 5.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

6.  Longitudinal Myelitis of a Neuro-Behçet Patient.

Authors:  Qi Tang; Jing Tian
Journal:  Arch Rheumatol       Date:  2015-11-03       Impact factor: 1.472

Review 7.  The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis.

Authors:  Aksel Siva; Sabahattin Saip
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

8.  Rapid, complete and sustained response to corticosteroids and pulse cyclophosphamide therapy in a patient with behçet and central nervous disease.

Authors:  Concepción M Nuñez-Sotelo; Luis A Gutiérrez-Gonzalez; Martín A Rodriguez
Journal:  Maedica (Buchar)       Date:  2012-12

Review 9.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 10.  The utility of tumour necrosis factor blockade in orphan diseases.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.